α7烟碱型乙酰胆碱受体激动剂AR-R17779通过抑制巨噬细胞促炎活性减轻创伤诱导的肺上皮糖萼损伤
研究采用C57BL/6小鼠多发性创伤模型(肺挫伤加肝挤压伤),伤后立即腹腔注射AR-R17779(25 mg/kg),24小时后取肺组织行组织学和硫酸肝素免疫荧光评估急性肺损伤。结果显示AR-R17779减轻多发性创伤所致组织学急性肺损伤及肺上皮糖萼硫酸肝素丢失。体外实验中,AR-R17779剂量依赖性抑制LPS处理的巨噬细胞STAT3磷酸化和肿瘤坏死因子释放;共培养中,经AR-R17779处理的LPS刺激巨噬细胞较单用LPS组减少上皮糖萼降解。作者结论认为其作用可能源于抑制巨噬细胞促炎活性,并提出未来应将其作为复苏辅助手段进行研究。
要点
- 小鼠多发性创伤(肺挫伤加肝挤压伤)模型中,伤后立即腹腔注射AR-R17779 25 mg/kg,24小时后组织学急性肺损伤减轻。
- AR-R17779减轻多发性创伤诱导的肺上皮糖萼硫酸肝素丢失。
- 体外AR-R17779剂量依赖性抑制LPS处理的巨噬细胞STAT3磷酸化及肿瘤坏死因子释放。
- 共培养中经AR-R17779处理的LPS刺激巨噬细胞较单用LPS组减少上皮糖萼降解。
- 作者认为未来应测试AR-R17779作为复苏辅助手段,以限制创伤后失调的巨噬细胞活化与急性肺损伤。
适用人群与场景
- C57BL/6小鼠多发性创伤模型,由肺挫伤和肝挤压伤组成。
处置流程与药物剂量
- 伤后立即腹腔注射AR-R17779,剂量25 mg/kg。
- 伤后24小时取肺组织,用组织学及硫酸肝素免疫荧光评估急性肺损伤。
研究设计与关键结果
- 研究类型为动物实验(小鼠多发性创伤模型)及体外共培养研究;AR-R17779组伤后立即腹腔注射25 mg/kg,24小时后组织学急性肺损伤及肺上皮糖萼硫酸肝素丢失均减轻。
- 体外实验中AR-R17779剂量依赖性抑制LPS处理的巨噬细胞STAT3磷酸化和肿瘤坏死因子释放。
- 共培养中经AR-R17779处理的LPS刺激巨噬细胞较单用LPS组减少上皮糖萼降解。
证据类型、等级与局限
- 证据类型:动物实验与体外研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为未来应测试AR-R17779作为复苏辅助手段,以限制创伤后失调的巨噬细胞活化与急性肺损伤。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute lung injury (ALI) after trauma is associated with alveolar dysfunction that causes significant morbidity with limited treatment options. We have shown that AR-R17779, a small molecule agonist of the α7 nicotinic acetylcholine receptor highly expressed on macrophages, prevents lung edema in preclinical models of injury. The mechanism by which AR-R17779 attenuates trauma-induced ALI is unknown. We hypothesized that AR-R17779 decreases trauma-induced ALI by limiting macrophage activation and preventing lung epithelial glycocalyx breakdown.
METHODS: C57BL/6 mice underwent a polytrauma model consisting of lung contusion and liver crush injury with cohorts treated with an intraperitoneal dose of AR-R17779 (25 mg/kg) immediately following polytrauma. Lungs were harvested 24 hours postinjury for evaluation of ALI using histology and immunofluorescence of heparan sulfate (HS), a key component of the glycocalyx. In vitro coculture studies were performed to assess the impact of AR-R17779 on the activation of macrophages by lipopolysaccharide (LPS) and its effects on the lung epithelial glycocalyx by immunoblotting, enzyme-linked immunosorbent assay, and HS expression.
RESULTS: AR-R17779 attenuated polytrauma-induced histological ALI and loss of HS from the lung epithelial glycocalyx. In vitro, AR-R17779 dose-dependently suppressed signal transducer and activator of transcription 3 phosphorylation and tumor necrosis factor release from LPS-treated macrophages. In coculture studies, treating LPS-stimulated macrophages with AR-R17779 decreased epithelial glycocalyx degradation compared with macrophages treated with LPS alone.
CONCLUSION: AR-R17779 attenuated trauma-induced ALI by preventing lung epithelial glycocalyx breakdown, which may result from the suppression of macrophage proinflammatory activity. Future research should test AR-R17779 as an adjunct to resuscitation aimed at limiting dysregulated macrophage activation and ALI after trauma.
参考来源
- Nakatsutsumi K, Choi W, Heard M, et al. AR-R17779, an agonist of alpha-7 nicotinic acetylcholine receptor, attenuates trauma-induced lung epithelial glycocalyx injury by suppressing macrophage proinflammatory activity. J Trauma Acute Care Surg. 2025. PMID: 41417716. doi:10.1097/TA.0000000000004829
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。